Saturday, April 4, 2026
30 C
Bengaluru

Sachhin Misshra has been elevated to the role of President at Akumentis Healthcare.

Sachhin Misshra has been elevated to the role of President at Akumentis Healthcare.

With over nine years at the organization and more than 25 years of experience in the pharmaceutical industry, he brings deep insight into how innovation and focused sales and marketing strategies can drive meaningful improvements in patient outcomes.

In his new role, he will lead the company’s core “One Gynaec” mission. By aligning its specialized divisions, Akumentis Healthcare aims to build a unified, high-impact ecosystem dedicated to gynaecology and infertility. He will be steering the organization toward scaling new milestones, introducing transformative products, and strengthening its position within the Indian pharmaceutical landscape.

He also expressed his gratitude to Executive Director Mr. Kanishk Jain, CEO Mr. Ajay Dhiman, along with mentors, colleagues, and the broader healthcare community for their continued trust and support.

Hot this week

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India

How the 2026 U.S. tariff action on branded drugs...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Topics

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?

As over 50 generic versions of the blockbuster weight-loss...
spot_img

Related Articles

spot_imgspot_img